NasdaqHealth CareHealth Care EquipmentS&P SmallCap 600
$16.91
-1.08 (-6.00%)
Close of Nov 06, 2026 · end-of-day data
TNDM 8-K filings in 2025
Every material Form 8-K Tandem Diabetes Care filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Tandem Diabetes Care appointed Sandra Beaver as an independent director effective November 7, 2025, expanding the board from eight to nine members. She will serve on the Audit Committee and the Cybersecurity and Data Privacy Committee, and the filing describes her as a finance executive with more than 20 years of experience.
Sandra Beaver, age 48, appointed to the board effective November 7, 2025, with a term expiring at the 2026 annual meeting
Initial RSU award for 20,242 shares valued at $300,000 under the non-employee director policy
Annual retainer of $60,000 plus $11,000 for Audit Committee and $6,000 for Cybersecurity and Data Privacy Committee service
Tandem Diabetes Care reported third quarter 2025 results for the period ended September 30, with worldwide sales up to $249.3 million from $244.0 million a year earlier and a GAAP net loss of $21.2 million, down from $23.3 million. The company reaffirmed its full year 2025 guidance, including sales of approximately $1.0 billion, which keeps the outlook unchanged for shareholders.
Worldwide sales were $249.3 million, including $73.6 million outside the United States, versus $244.0 million in the third quarter of 2024.
GAAP net loss was $21.2 million, or $0.31 per share, compared with a net loss of $23.3 million, or $0.35 per share, a year earlier.
GAAP gross margin was 54%, compared with 51% a year earlier.
For 2025, the company reaffirmed guidance for sales of approximately $1.0 billion and an adjusted EBITDA margin of approximately negative 5% of sales.
Tandem Diabetes reported second quarter 2025 worldwide sales of $240.7 million, up from $221.9 million a year earlier, but its GAAP net loss widened to $52.4 million from $30.8 million, including a $20.0 million litigation and settlement expense. The company also gave full-year 2025 guidance of about $1.0 billion in sales and a 53% to 54% gross margin, which matters to shareholders because it sets the company's expected revenue and margin path for the year.
Q2 2025 worldwide sales were $240.7 million, including $70.5 million outside the United States, compared with $221.9 million in Q2 2024.
GAAP net loss per share was $0.78, compared with $0.47 a year earlier; GAAP operating loss was $51.8 million.
2025 guidance calls for about $1.0 billion in sales, with about $700 million in the United States and about $300 million outside it.
Adjusted EBITDA margin for 2025 was recast from about 3% to about negative 5%, reflecting an 8 percentage point impact from a first quarter acquired in-process research and development charge.
On May 21, 2025, Tandem Diabetes and Roche entities agreed to settle all patent disputes over the t:slim X2 pump, terminating pending actions before Unified Patent Court divisions in France and Germany. The Tandem entities will pay $36 million over five years, starting with an $8 million initial payment, and the parties granted each other 10-year licenses to insulin delivery patents. The same day, shareholders elected all eight directors, approved executive pay on an advisory basis, and ratified Ernst & Young as auditor.
Settlement resolves disputes over the t:slim X2 pump and two Roche-related EP patents, ending pending actions in France and Germany.
Tandem entities will pay $36 million over five years: an $8 million initial payment, then four equal annual installments.
Cross-licenses of insulin delivery system patents run for 10 years from the May 21, 2025 effective date.
At the May 21, 2025 annual meeting, executive pay was approved with 54,337,934 for and 1,598,126 against, and shareholders chose an annual say-on-pay vote.
Tandem Diabetes reported first quarter 2025 worldwide sales of $234.4 million, up 22% from $191.7 million a year earlier, and reaffirmed its 2025 GAAP sales guidance of $997 million to $1.007 billion. GAAP net loss widened to $130.6 million, or $1.97 per share, from $42.7 million, or $0.65 per share, mainly due to $75.2 million of acquired in-process research and development expenses, so sales growth and the larger loss point in different directions for shareholders.
Worldwide sales rose to $234.4 million from $191.7 million; U.S. pump sales rose 19% on a GAAP basis.
GAAP net loss was $130.6 million, compared with $42.7 million; non-GAAP net loss was $44.2 million, compared with $41.6 million.
Adjusted EBITDA was negative $4.7 million, compared with negative $14.4 million a year earlier.
Full-year 2025 GAAP sales guidance of $997 million to $1.007 billion was reaffirmed.
Tandem Diabetes reported fourth-quarter and full-year 2024 results and gave 2025 guidance. GAAP sales rose 26% for the year to $940.2 million, and the net loss narrowed to $96.0 million from $222.6 million. The company expects 2025 sales of approximately $997 million to $1.007 billion, with adjusted EBITDA margin of about 3 percent for the full year.
Q4 2024 GAAP sales grew 44% to $282.6 million; non-GAAP sales grew 21% to $252.4 million, with GAAP results affected by the Tandem Choice program.
Q4 2024 GAAP net income was $0.8 million, or $0.01 per share, compared with a net loss of $30.0 million, or $0.46 per share, a year earlier.
Full-year 2024 GAAP net loss was $96.0 million, or $1.47 per share, compared with $222.6 million, or $3.43 per share, in 2023.
2025 guidance: full-year sales of approximately $997 million to $1.007 billion and first-quarter sales of approximately $219 million to $224 million.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Tandem Diabetes Care filing is on SEC EDGAR ↗. 8-K briefs of other companies →